AP
APLS
HealthcareApellis Pharmaceuticals, Inc.
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
10
M&ABullishPer-CompanyApr 1, 2026
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion in All-Cash Deal
- ▸Biogen to acquire Apellis for $41 per share in all-cash deal
- ▸Transaction value $5.6 billion, representing 86% premium to 90-day average
- ▸Deal includes contingent payments tied to Syfovre sales milestones
- ▸Apellis 2025 revenue $689 million with mid-to-high teens growth projected
- ▸Apellis shares surged 135.4% following acquisition announcement
10
M&ABullishPer-CompanyApr 1, 2026
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion at $41 per share
- ▸Acquisition price $41 per share, total value $5.6 billion
- ▸Shareholders to receive additional $2 per share contingent on Syfovre sales milestones
- ▸Transaction expected to close in Q2
- ▸Syfovre and Empaveli combined 2025 net sales reached $689 million
- ▸Stock surged 135.4% to $40.23 following acquisition announcement